ViaNautis Bio is a Cambridge, UK-based biotechnology company developing polyNaut, a platform of targeted polymer nanovesicles (tPNVs) for precise, non-viral delivery of genetic medicines. The nanobody-guided vesicles deliver DNA and mRNA payloads to specific cells and tissues - including regenerative payloads at and around spinal cord lesion sites - with applications across CNS, immunology, oncology and respiratory diseases. Led by CEO Adi Hoess, the company raised a $25M Series A in 2023 from investors including 4BIO Capital, BGF and UCB Ventures and has a strategic collaboration with Eli Lilly.
1
Round
1
Industry
3
Tags
Sep 9, 2026
Latest raise
Funding activity · 1 round
Sep 9, 2026
$-1
Undisclosed
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
